

Comparison of Methicillin-Resistant *Staphylococcus aureus* Community-Acquired and Healthcare-Associated Pneumonia

Ah Young Leem,¹ Won Jai Jung,² Young Ae Kang,¹ Seon Cheol Park,³ Young Jae Kim,¹
Eu Dong Hwang,¹ Eun Young Kim,¹ Kyung Soo Jung,¹ Moo Suk Park,¹ Song Yee Kim,¹
Young Sam Kim,¹ Se Kyu Kim,¹ Joon Chang,¹ and Ji Ye Jung¹

¹Division of Pulmonology, Department of Internal Medicine, Institute of Chest Disease, Yonsei University College of Medicine, Seoul;

²Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University College of Medicine, Seoul;

³Division of Pulmonology, Department of Internal Medicine, Institute of Chest Disease, National Health Insurance Corporation Ilsan Hospital, Goyang, Korea.

Received: July 17, 2013

Revised: October 7, 2013

Accepted: November 5, 2013

Corresponding author: Dr. Ji Ye Jung,
Division of Pulmonology,
Department of Internal Medicine,
Institute of Chest Disease, Severance Hospital,
Yonsei University College of Medicine,
50-1 Yonsei-ro, Seodaemun-gu,
Seoul 120-752, Korea.
Tel: 82-10-3141-2576, Fax: 82-2-393-6884
E-mail: STOPYES@yuhs.ac

The authors have no financial conflicts of interest.

Purpose: Methicillin-resistant *Staphylococcus aureus* (MRSA) is recognized as an important cause of not only healthcare-associated pneumonia (HCAP) but also community-acquired pneumonia (CAP). We determined the impact of MRSA on differences in clinical characteristics, courses, and outcomes between CAP and HCAP. **Materials and Methods:** We conducted a retrospective observational study on 78 adult patients admitted with MRSA pneumonia at a university-affiliated tertiary hospital between January 2008 and December 2011. We compared baseline characteristics, chest radiographs, treatment outcomes, and drug resistance patterns between the CAP and HCAP groups. **Results:** Of the 78 patients with MRSA pneumonia, 57 (73.1%) were HCAP and 21 (26.9%) were CAP. MRSA infection history in the previous year (29.8% vs. 14.3%, $p=0.244$) tended to be more common in HCAP than in CAP. Despite similar Pneumonia Severity Index scores (151 in CAP vs. 142 in HCAP), intubation rates (38.1% vs. 17.5%; $p=0.072$) and intensive care unit admission (42.9% vs. 22.8%; $p=0.095$) tended to be higher in the CAP group, while 28-day mortality was higher in the HCAP group (14.3% vs. 26.3%; $p=0.368$), although without statistical significance. All patients showed sensitivity to vancomycin and linezolid; meanwhile, HCAP patients showed greater resistance to gentamicin than CAP patients (58.3% vs. 16.6%; $p=0.037$). The median total hospital charges were 6899 American dollars for CAP and 5715 American dollars for HCAP ($p=0.161$). **Conclusion:** MRSA pneumonia showed significantly differences in baseline characteristics, chest radiographs, treatment outcomes, and medical expenses between HCAP and CAP groups.

Key Words: Pneumonia, methicillin-resistant *Staphylococcus aureus*, community-acquired pneumonia, healthcare-associated pneumonia

© Copyright:

Yonsei University College of Medicine 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Methicillin-resistant *Staphylococcus aureus* (MRSA) is a well-known cause of hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia, repre-

senting 20–40% of infections.^{1,2} Unlike the previous confinement of MRSA to healthcare settings, MRSA has also emerged as an important pathogen in non-nosocomial pneumonia, comprising up to 20% of healthcare-associated pneumonia (HCAP) cases and up to 10% of community-acquired pneumonia (CAP) cases.³⁻⁷

MRSA pneumonia is likely to be severe and life-threatening, with high mortality, compared with non-MRSA pneumonia.⁸⁻¹⁰ Rapidly progressive necrotizing pneumonia, due to community-associated MRSA, is notable for its high morbidity and mortality, even in relatively young and previously healthy patients.¹¹ Although treatment of MRSA pneumonia is typically universal, starting with glycopeptide antimicrobial therapy, regardless of the source of infection (i.e., hospital- or community-acquired) different risk factors, transmission, clinical courses, and antibiotic resistance patterns have been reported between hospital-acquired (HA-) and community-acquired MRSA (CA-MRSA) pneumonia.^{12,13}

Recently, HCAP and CAP have garnered greater concern; however, the exact incidence of non-nosocomial pneumonia with MRSA is difficult to determine. Although there are a number of case reports and small case series in the literature, there has yet to be any substantial epidemiologic study. HCAP has been described as pneumonia more similar to HAP than CAP in terms of epidemiological patterns and prognosis.¹⁴⁻¹⁶ However, the influence of MRSA on the different characteristics of HCAP and CAP is not well-known.

As CAP and HCAP are classified as different types of pneumonia, the purpose of this study was to examine the incidences of MRSA CAP and MRSA HCAP. We also attempted to determine the impact of MRSA on differences in clinical characteristics, treatment outcomes, and medical expenses between CAP and HCAP.

MATERIALS AND METHODS

Study design and subjects

We conducted a retrospective observational study on adult patients (≥ 20 years old) admitted with MRSA pneumonia at Severance Hospital (a university-affiliated tertiary hospital) in South Korea between January 2008 and December 2011. Among 943 pneumonia patients with identified pathogens, 78 patients with MRSA pneumonia were included in this study. Patients were classified into CAP or HCAP groups. We compared baseline characteristics, treatment outcomes, medical expenses, and drug resistance patterns between the

groups. This study protocol was approved by the Institutional Review Board of Severance Hospital.

Definitions

Pneumonia was defined as the presence of a new infiltrate on chest radiograms with at least one of the following symptoms: fever or hypothermia, cough with or without sputum, chest pain, dyspnea, or altered breath sounds on auscultation.¹⁷

CAP and HCAP were defined according to American Thoracic Society/Infectious Diseases Society America (ATS/IDSA) guidelines.¹⁸ HCAP included patients with at least one of the following criteria: hospitalization within 90 days before the pneumonia diagnosis, admission from a nursing home or a long-term care facility, infusion therapy such as that with intravenous antibiotics, chemotherapy, or wound care within 30 days before the pneumonia diagnosis, and/or chronic hemodialysis or peritoneal dialysis.¹⁸

We defined immunosuppressed patients as those that comprised at least one of following: daily treatment with systemic corticosteroids (≥ 15 mg of prednisone/day for more than 1 month) or combination therapy with low-dose corticosteroids and other immunosuppressants (azathioprine, mycophenolate, methotrexate, cyclosporine, or cyclophosphamide), seropositivity for human immunodeficiency virus, receipt of a solid organ or bone marrow transplant, radiation therapy or chemotherapy for an underlying malignancy within 6 months prior to hospital admission, or diagnosis with an underlying acquired immune deficiency disorder.¹⁹

Total hospital charges included all medical expenses during hospitalization, except charges for a hospital room.

Microbiological studies

Pathogens from sputum, blood, bronchoalveolar lavage fluid, pleural effusion, or lung abscesses were investigated using standard microbiological procedures. Blood cultures were considered as an etiological diagnosis if there was no other infection source for a positive blood culture. Sputum samples were cultured using semi-quantitative manner and an etiological diagnosis was confirmed when a predominant microorganism was isolated from group 4 or 5 sputum, according to Murray and Washington's grading system.²⁰ MRSA pneumonia was defined as pneumonia coinciding with isolation of MRSA as the only potential pathogen. The qualitative polymerase chain reaction (PCR) amplification of *mecA* is a rapid and sensitive method for detecting MRSA, but cultures were used because of high rate of false positives in PCR method.²¹ VITEK system was used to evaluate mini-

imum inhibitory concentrations (MICs) of antimicrobial agents.

Patients were treated in accordance with ATS/IDSA guidelines although the detailed antibiotic regimens were decided by the attending physician, taking into consideration patient risk factors and the severity of the disease.

Statistics

We conducted univariate analyses with the χ^2 test or Fisher's exact test for categorical variables and the Mann-Whitney U test for continuous variables. Non-normally distributed variables are presented as medians (interquartile range). All tests were two-sided, and a p value <0.05 was deemed to indicate statistical significance. SPSS software (ver. 18.0; SPSS Inc., Chicago, IL, USA) was used for all statistical analyses.

RESULTS

Incidence of MRSA in culture-positive CAP and HCAP during 2008–2011

The total number of hospitalized patients with non-nosocomial culture-positive pneumonia was 943 (496 in CAP, 447 in HCAP) between January 2008 and December 2011. The total numbers of culture-positive CAP and HCAP for each year are as follows: 86 and 79 in 2008, 105 and 105 in 2009, 133 and 108 in 2010, and 172 and 155 in 2011, respectively. The incidence of MRSA in non-nosocomial culture-positive CAP and HCAP was 4.2% and 12.8% over the 4 years. The change in the proportion of MRSA is shown in Fig. 1. While the proportion of MRSA in culture-positive CAP increased from 2.9% in 2009 to 4.7% in 2011 that in culture-positive HCAP fluctuated between 7.6% and 19.4%. MRSA pneumonia was observed most frequently in April (16.7%), November (12.8%), and December (11.5%).

Baseline characteristics

Among the 78 patients with MRSA pneumonia, 21 (26.9%) presented with CAP and 57 (73.1%) presented with HCAP. Baseline characteristics of the patients with MRSA CAP and MRSA HCAP are listed in Table 1. Median ages in the MRSA CAP and MRSA HCAP groups were 73 (60.5–77.5) and 71 (66.0–79.5) years old, respectively ($p=0.491$). Males were dominant in both groups (76.2% in MRSA CAP vs. 73.7% in MRSA HCAP; $p=1.000$) and hypertension was the most predominant underlying disease in both groups (52.4% in MRSA CAP vs. 57.9% in MRSA HCAP; $p=0.798$). Hy-

poxemia at admission was observed in more than half of the patients in both groups (66.7% in MRSA CAP vs. 61.4% in MRSA HCAP; $p=0.794$), while shock (38.1% vs. 21.1%; $p=0.15$) and MRSA bacteremia (28.6% vs. 17.5%; $p=0.346$) tended to occur more in MRSA CAP than in MRSA HCAP. Immunosuppressed status (35.1% vs. 19.0%; $p=0.269$) and previous MRSA infection history within 1 year (29.8% vs. 14.3%; $p=0.244$) tended to be more common in MRSA HCAP than in MRSA CAP, but without statistical significance. CURB65 scores and Pneumonia Severity Index scores did not differ between the groups.

Chest radiographs

Chest radiograph findings did not differ between the groups. Multiple infiltrates were the most common finding in both groups (52.4% in MRSA CAP and 40.4% in MRSA HCAP; $p=0.342$) (Table 2). Diffuse bilateral infiltrates tended to be more common in HCAP than in CAP (38.6% vs. 23.8%; $p=0.223$). Pleural effusion was observed in about one-fifth of patients in both groups, but no empyema was observed.

Antibiotic treatment and clinical outcomes

Treatments and clinical outcomes of pneumonia patients with MRSA CAP and MRSA HCAP are shown in Table 3. Treatment with glycopeptides within 1 day was higher for MRSA CAP than for MRSA HCAP, but without statistical significance (28.6% vs. 14.0%; $p=0.184$). Intubation rates (38.1% vs. 17.5%; $p=0.072$) and intensive care unit (ICU) admission




Fig. 1. Proportion of MRSA culture-positive community-acquired pneumonia and healthcare-associated pneumonia from 2008 to 2011. The proportions of MRSA in culture-positive CAP and HCAP in each year were as follows: 7% (6/86) and 10.1% (8/79) in 2008, 2.9% (3/105) and 7.6% (8/105) in 2009, 3.0% (4/133) and 19.4% (21/108) in 2010, and 4.7% (8/172) and 12.9% (20/155) in 2011, respectively. CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; MRSA, methicillin-resistant *Staphylococcus aureus*.

Table 1. Baseline Characteristics of Patients with MRSA CAP and MRSA HCAP*

Baseline characteristics	CAP (n=21)	HCAP (n=57)	p value
Age, yrs	73.0 (60.5–77.5)	71.0 (66.0–79.5)	0.491
Male	16 (76.2)	42 (73.7)	1
Female	5 (23.8)	15 (26.3)	
Underlying diseases			
Diabetes mellitus	9 (42.9)	21 (36.8)	0.794
Chronic lung disease [†]	4 (19.0)	16 (28.1)	0.562
Cerebrovascular accident	5 (23.8)	17 (29.8)	0.778
Renal disease	5 (23.8)	9 (15.8)	0.508
Hypertension	11 (52.4)	33 (57.9)	0.798
Cardiovascular disease	5 (23.8)	16 (28.1)	0.781
Liver disease	3 (14.3)	3 (5.3)	0.335
Rheumatologic disease	1 (4.8)	2 (3.5)	1
Malignancy	7 (33.3)	29 (50.9)	0.206
Solid organ malignancy	5 (23.8)	27 (47.4)	0.073
Hematological malignancy	2 (9.5)	2 (3.5)	0.292
Clinical manifestations and parameters			
Bloody sputum	0 (0)	1 (1.8)	1
Confusion (decreased consciousness)	5 (23.8)	12 (21.1)	0.766
Shock at onset	8 (38.1)	12 (21.1)	0.15
PaO ₂ <60 mm Hg, SpO ₂ <90%, or need for oxygen therapy	14 (66.7)	35 (61.4)	0.794
Acute renal failure at onset	4 (19.0)	9 (15.8)	0.74
Immunosuppressed [‡]	4 (19.0)	20 (35.1)	0.269
MRSA history in previous 1 yr	3 (14.3)	17 (29.8)	0.244
Tube feeding	1 (4.8)	11 (19.3)	0.164
Intubated in ER	4 (19.0)	7 (12.3)	0.475
Laboratory findings			
White blood cell	12260 (9230–19600)	11340 (7285–14965)	0.168
Hematocrit <30%	5 (23.8)	16 (28.1)	0.781
Blood urea nitrogen >30 mg/dL	7 (33.3)	18 (31.6)	1
Sodium <130 mmol/L	6 (28.6)	9 (15.8)	0.213
Glucose >250 mg/dL	4 (19.0)	6 (10.5)	0.445
pH <7.35	2 (9.5)	5 (8.8)	1
Disease severity			
CURB65	2 (1–3)	2 (1–3)	0.856
Pneumonia Severity Index	151 (129–158)	142 (125–165)	1.000

CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; MRSA, methicillin-resistant *Staphylococcus aureus*; ER, emergency room.

*Data are presented as numbers (percentages) or medians (interquartile range) unless otherwise indicated.

[†]Chronic lung disease includes asthma, chronic obstructive pulmonary disease, and structural lung diseases, such as bronchiectasis and interstitial lung disease.

[‡]Immunosuppression included the following: 1) daily administration of systemic corticosteroids (at least 15 mg of prednisone per day for more than 1 month or combination therapy with low-dose corticosteroids and other immunosuppressants, including azathioprine, mycophenolate, methotrexate, cyclosporine, or cyclophosphamide), 2) seropositivity for human immunodeficiency virus, 3) received a solid organ transplant or bone marrow transplant, 4) treated with radiation therapy or chemotherapy for an underlying malignancy during the 6 months prior to hospital admission, or 5) an underlying acquired immune deficiency disorder.

(42.9% vs. 22.8%; $p=0.095$) tended to be higher in MRSA CAP, while 28-day mortality tended to be higher in MRSA HCAP (14.3% vs. 26.3%; $p=0.368$). The median total hospital charges were 6899 American dollars in MRSA CAP and 5715 American dollars in MRSA HCAP ($p=0.161$).

Drug resistance patterns

Drug resistance patterns of MRSA pathogens in MRSA CAP and MRSA HCAP are shown in Table 4. Comparing various drugs resistances, MRSA HCAP showed significantly more resistance to gentamicin than MRSA CAP (58.3% vs. 16.6%;

Table 2. Chest X-Ray Findings in Patients with MRSA CAP and MRSA HCAP*

Chest X-ray findings	CAP (n=21)	HCAP (n=57)	p value
Single infiltrate	6 (28.6)	15 (26.3)	0.842
Multiple infiltrates	11 (52.4)	23 (40.4)	0.342
Diffuse bilateral infiltrate	5 (23.8)	22 (38.6)	0.223
Cavitation	0 (0)	1 (1.8)	0.541
Pleural effusion	4 (19.0)	13 (22.8)	0.721

CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; MRSA, methicillin-resistant *Staphylococcus aureus*.

*Data are presented as numbers (percentages).

Table 3. Treatment and Clinical Outcomes of Patients with MRSA CAP and MRSA HCAP*

Treatment/clinical outcomes	CAP (n=21)	HCAP (n=57)	p value
Treatment with glycopeptide within 1 day	6 (28.6)	8 (14.0)	0.184
Clinical outcomes			
28-day mortality	3 (14.3)	15 (26.3)	0.368
Intubation	8 (38.1)	10 (17.5)	0.072
ICU admission	9 (42.9)	13 (22.8)	0.095
Duration of ICU stay, days	17.0 (5.0–26.0)	15.0 (12.0–39.0)	0.512
Duration of hospital stay, days	23.0 (15.5–61.5)	28.0 (16.5–51.5)	0.292
Total hospital charge, American dollars (\$)†			
Mean±SD	19060±21868	11752±16330	-
Median	6899 (4403–27849)	5715 (3058–11877)	0.108

CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; MRSA, methicillin-resistant *Staphylococcus aureus*; SD, standard deviation; ICU, intensive care unit.

*Data are presented as numbers (percentages) or medians (interquartile range) unless otherwise indicated.

†Total hospital charges included all medical expenses during hospitalization except charges for the hospital room.

$p=0.037$). Ciprofloxacin (78.5% vs. 66.7%; $p=0.542$) and clindamycin (83.9% vs. 61.9%; $p=0.079$) showed tendencies for more resistance in MRSA HCAP than in MRSA CAP. Resistance to rifampicin was observed only in MRSA HCAP, with an incidence of 2.7%, and the proportion of resistance to trimethoprim-sulfamethoxazole was also low in both groups (4.8% in MRSA CAP and 7.4% in MRSA HCAP; $p=0.826$). All patients showed sensitivity to vancomycin and linezolid. For vancomycin, the MIC was 2 µg/mL or less in both groups. For linezolid, the MIC was 2 µg/mL or less in all MRSA CAP cases, while 8.3% (3/36) of MRSA HCAP cases showed an MIC of 4 µg/mL or less.

DISCUSSION

We compared clinical characteristics, outcomes, and drug resistance patterns between MRSA CAP and MRSA HCAP from 2008 to 2011. Baseline characteristics, initial clinical manifestations, including radiological findings, disease severity, clinical outcomes, and medical expenses were similar between the groups. More patients with MRSA HCAP tended to show resistance to ciprofloxacin, clindamycin, and

gentamicin. However, all MRSA isolates examined showed susceptibility to vancomycin and linezolid.

There are several reports on comparisons of CA-MRSA and HA-MRSA.²² However, there are few detailed reports about MRSA HCAP, because HCAP only recently became a defined group, since 2005, and is composed of heterogeneous patients with varying severities of illness and different reasons for contact with the healthcare environment. Previous studies have suggested that the characteristics of HCAP are more similar to those of HAP than CAP. Nevertheless, MRSA infection is frequently a fatal illness with high mortality, regardless of the origin of infection. Thus, we sought to compare the characteristics and clinical outcomes of MRSA CAP and MRSA HCAP.

In previous studies, incidences of MRSA HCAP and MRSA CAP have been reported up to 30.6% and 14.6%, respectively.^{3-5,19,23,24} While the incidence of MRSA HCAP fluctuated from 7.6% to 19.4% over the 4 years in our study that of MRSA CAP increased since 2009, from 2.9% to 4.7%. Fluctuations in MRSA HCAP incidence were likely associated with local patterns of nosocomial pathogens during the period because most of the patients with HCAP had experienced repeated exposure to the hospital. The preva-

Table 4. Drug Resistance of Patients with MRSA CAP and MRSA HCAP*

Antibiotics	CAP (n=21)	HCAP (n=57)	p value
Arbekacin	0/19 (0)	0/53 (0)	0.658
Ciprofloxacin	14/21 (66.7)	44/56 (78.5)	0.542
Clindamycin	13/21 (61.9)	47/56 (83.9)	0.079
Erythromycin	17/21 (81.0)	52/56 (92.8)	0.329
Fusidic Acid	4/12 (33.3)	21/36 (58.3)	0.417
Gentamicin	2/12 (16.6)	21/36 (58.3)	0.037
Inducible Clindamycin Resistance	3/12 (25.0)	8/36 (22.2)	0.938
Mupirocin	0/12 (0)	1/36 (2.7)	0.922
Nitrofurantoin	0/12 (0)	1/35 (2.8)	1
Oxacillin	12/12 (100)	36/36 (100)	0.794
Cefoxitin Screen (+) [†]	20/20 (100)	56/56 (100)	0.469
Penicillin G	19/21 (90.5)	54/56 (96.4)	0.487
Quinupristin/dalfopristin	0/20 (0)	0/55 (0)	1
Rifampicin	0/12 (0)	1/36 (2.7)	0.922
Co-trimoxazole	1/21 (4.8)	4/54 (7.4)	0.826
Teicoplanin	0/21 (0)	0/56 (0)	1
Tetracycline	13/21 (61.9)	36/56 (64.2)	0.751
Tigecycline	0/12 (0)	0/36 (0)	0.794
Telithromycin	4/12 (33.3)	23/35 (65.7)	0.149
Vancomycin	0/21 (0)	0/56 (0)	1
MIC, ≤0.5 µg/mL	5/12 (41.7)	16/35 (45.7)	
≤1 µg/mL	5/12 (41.7)	9/35 (25.7)	
≤1.5 µg/mL	0 (0)	1/35 (2.9)	
≤2 µg/mL	2/12 (16.7)	9/35 (25.7)	
Linezolid	0/21 (0)	0/55 (0)	1
MIC, ≤1 µg/mL	0/12 (0)	1/36 (2.8)	
≤2 µg/mL	12/12 (100)	32/36 (88.9)	
≤4 µg/mL	0/12 (0)	3/36 (8.3)	

CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; MRSA, methicillin-resistant *Staphylococcus aureus*; MIC, minimum inhibitory concentration.

*Data are presented as numbers (percentages).

[†]In a previous study, a cefoxitin screen showed higher sensitivity and specificity for detection of methicillin resistance, especially in low-level-resistant *S. aureus* strains.

lence of MRSA CAP in 2008 was as high as 7.0% because the overall number of pneumonia cases with culture-positive pathogens was low due to relatively less effort being devoted to detecting atypical pathogens using serological tests. Thus, the relative proportion of MRSA was high, compared with other periods.

CA-MRSA pneumonia is associated with an influenza-like prodrome; severe respiratory symptoms with a rapidly progressive pneumonia, evolving to acute respiratory distress syndrome; high fever (body temperature $\geq 39^{\circ}\text{C}$); hemoptysis; hypotension; leucopenia; and a chest radiograph showing multilobar cavitating alveolar infiltrates.^{1,22} Young age has been a remarkable feature of CA-MRSA pneumonia in European and US studies.²⁵⁻²⁷ However, we demonstrated different features of MRSA CAP from previous studies. The

ages of patients in the present study were not remarkably young, with an average in the 70 s, likely the result of population aging to the point where the level of immunocompromised subjects increased. Moreover, severe illness features of high fever and hemoptysis were not frequent, although hypotension was seen in about 40% of MRSA CAP cases. No patient with MRSA CAP showed cavitation on a chest X-ray.

MRSA HCAP in this study showed characteristics similar to the previously reported HA-MRSA pneumonia. The patients were elderly, with the average age in the 70 s, and half of the patients had significant underlying diseases, such as malignancies. Moreover, most of the MRSA isolates from HCAP showed resistance to multiple antibiotics.²²

In this study, we compared MRSA CAP with MRSA HCAP. The average age was similar between the groups,

with male dominance. Immunocompromised status and MRSA infection history for the previous year tended to be more common in MRSA HCAP than MRSA CAP. Pneumonia Severity Index scores were similar due to more severe clinical status in MRSA CAP and more severe underlying disease in MRSA HCAP, resulting in higher intubation rates and ICU admission for MRSA CAP than for MRSA HCAP. Although the proportion of requests for “do not resuscitate” was similar in both groups (33.3% in MRSA CAP and 40.0% in MRSA HCAP; data not shown), 28-day mortality tended to be higher in MRSA HCAP, probably as a result of severe underlying diseases. Both groups frequently showed multiple infiltrates but few cavitations on chest X-rays.

Comparing drug resistance patterns, MRSA HCAP showed more resistance to gentamicin than MRSA CAP. Although MRSA in all patients was sensitive to vancomycin and linezolid, the proportion of MICs of 1 µg/mL or less tended to be higher in MRSA CAP than in MRSA HCAP (83.4% vs. 71.4%).

HCAP is generally associated with higher mortality and higher healthcare costs than CAP, but MRSA infection did not show significant differences in clinical features and outcomes between HCAP and CAP.^{14-16,28} Total hospital charges were slightly higher for MRSA CAP than for MRSA HCAP, but the differences were not statistically significant. This might have resulted from more patients with MRSA CAP receiving aggressive treatment, including intensive critical care, versus those with MRSA HCAP.

The present study has several limitations. First, the definition of MRSA CAP in this study differs from that in several studies where CA-MRSA was restricted to only Pantone-Valentine leukocidin (PVL)-positive *S. aureus*.^{1,22,25} Because of the retrospective method of this study, we were not able to analyze whether MRSA in CAP or HCAP produced PVL, which usually presents only in CA-MRSA. However, the purpose of this study was to compare the characteristics of MRSA CAP and MRSA HCAP, regardless of the presence of PVL. As the boundary between community and hospitals is blurring due to the back and forth movement of patients between them, the presence of PVL will not be limited to the community in the future. Moreover, a recent meta-analysis study reported that PVL genes were consistently associated with skin and soft-tissue infections, but were comparatively rare in pneumonia.²⁹ Second, this study was conducted at a single tertiary referral hospital, so our findings may not generally represent MRSA CAP. Third, we included only patients with pneumonia that required hospital-

ization; they were older than the general population and had higher rates of comorbidities. Finally, the sample size was small despite a 4-year study period because of the relatively low incidence of MRSA CAP. Significant differences may be expected with increased numbers of cases.

In summary, our study presents a comparison of clinical characteristics, outcomes, and drug resistance patterns between MRSA CAP and MRSA HCAP from 2008 to 2011. The incidence of MRSA CAP has increased, unlike that of MRSA HCAP. Although HCAP should be generally distinguished from CAP because of differing clinical features, MRSA infection seems to have broken the boundary between HCAP and CAP, and the severe, infectious features that MRSA possesses may surpass the supposed differences in disease severity and characteristics between HCAP and CAP.

REFERENCES

- Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis* 2008; 46 Suppl 5:S378-85.
- Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. *Infect Control Hosp Epidemiol* 2013;34:1-14.
- Park HK, Song JU, Um SW, Koh WJ, Suh GY, Chung MP, et al. Clinical characteristics of health care-associated pneumonia in a Korean teaching hospital. *Respir Med* 2010;104:1729-35.
- Schreiber MP, Chan CM, Shorr AF. Resistant pathogens in nonnosocomial pneumonia and respiratory failure: is it time to refine the definition of health-care-associated pneumonia? *Chest* 2010;137:1283-8.
- Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Hashimoto N, et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. *Chest* 2009;135:633-40.
- Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, Albrecht V, Limbago B, et al. Prevalence of methicillin-resistant *Staphylococcus aureus* as an etiology of community-acquired pneumonia. *Clin Infect Dis* 2012;54:1126-33.
- Rello J, Bodi M, Mariscal D, Navarro M, Diaz E, Gallego M, et al. Microbiological testing and outcome of patients with severe community-acquired pneumonia. *Chest* 2003;123:174-80.
- Lobo LJ, Reed KD, Wunderink RG. Expanded clinical presentation of community-acquired methicillin-resistant *Staphylococcus aureus* pneumonia. *Chest* 2010;138:130-6.
- Kallen AJ, Brunkard J, Moore Z, Budge P, Arnold KE, Fosheim G, et al. *Staphylococcus aureus* community-acquired pneumonia during the 2006 to 2007 influenza season. *Ann Emerg Med* 2009;53:358-65.
- Gillet Y, Vanhems P, Lina G, Bes M, Vandenesch F, Floret D, et al. Factors predicting mortality in necrotizing community-acquired

- pneumonia caused by *Staphylococcus aureus* containing Panton-Valentine leukocidin. *Clin Infect Dis* 2007;45:315-21.
11. Hidron AI, Low CE, Honig EG, Blumberg HM. Emergence of community-acquired methicillin-resistant *Staphylococcus aureus* strain USA300 as a cause of necrotising community-onset pneumonia. *Lancet Infect Dis* 2009;9:384-92.
 12. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant *Staphylococcus aureus* Infections in Adults and Children. *Clin Infect Dis* 2011;52:e18-55.
 13. Nathwani D, Morgan M, Masterton RG, Dryden M, Cookson BD, French G, et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant *Staphylococcus aureus* (MRSA) infections presenting in the community. *J Antimicrob Chemother* 2008;61:976-94.
 14. Mylotte JM. Nursing home-acquired pneumonia. *Clin Infect Dis* 2002;35:1205-11.
 15. Muder RR. Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. *Am J Med* 1998;105:319-30.
 16. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. *Ann Intern Med* 2002;137:791-7.
 17. Carratalà J, Fernández-Sabé N, Ortega L, Castellsagué X, Rosón B, Dorca J, et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. *Ann Intern Med* 2005;142:165-72.
 18. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 2005;171:388-416.
 19. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. *Antimicrob Agents Chemother* 2007;51:3568-73.
 20. Murray PR, Washington JA. Microscopic and bacteriologic analysis of expectorated sputum. *Mayo Clin Proc* 1975;50:339-44.
 21. Kim MH, Lee WI, Kang SY. Detection of methicillin-resistant *Staphylococcus aureus* in healthcare workers using real-time polymerase chain reaction. *Yonsei Med J* 2013;54:1282-4.
 22. Defres S, Marwick C, Nathwani D. MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia. *Eur Respir J* 2009;34:1470-6.
 23. Carratalà J, Mykietiuik A, Fernández-Sabé N, Suárez C, Dorca J, Verdaguer R, et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. *Arch Intern Med* 2007;167:1393-9.
 24. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. *Chest* 2005;128:3854-62.
 25. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, et al. Association between *Staphylococcus aureus* strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. *Lancet* 2002;359:753-9.
 26. Hageman JC, Uyeki TM, Francis JS, Jernigan DB, Wheeler JG, Bridges CB, et al. Severe community-acquired pneumonia due to *Staphylococcus aureus*, 2003-04 influenza season. *Emerg Infect Dis* 2006;12:894-9.
 27. Gonzalez BE, Hulten KG, Dishop MK, Lamberth LB, Hammerman WA, Mason EO Jr, et al. Pulmonary manifestations in children with invasive community-acquired *Staphylococcus aureus* infection. *Clin Infect Dis* 2005;41:583-90.
 28. Shorr AF, Haque N, Taneja C, Zervos M, Lamerato L, Kothari S, et al. Clinical and economic outcomes for patients with health care-associated *Staphylococcus aureus* pneumonia. *J Clin Microbiol* 2010;48:3258-62.
 29. Shallcross LJ, Fragaszy E, Johnson AM, Hayward AC. The role of the Panton-Valentine leukocidin toxin in staphylococcal disease: a systematic review and meta-analysis. *Lancet Infect Dis* 2013;13:43-54.